Abstract: Gefitinib (ZD1839), an orally active, first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations. By competitively binding to the ATP-binding site of the EGFR tyrosine kinase domain, gefitinib effectively blocks downstream signaling pathways, inducing cell cycle arrest and inhibiting tumor angiogenesis. Despite its initial robust clinical efficacy, the inevitable emergence of acquired resistance—predominantly driven by the T790M secondary mutation, MET amplification, and bypass signaling activation—limits its long-term utility. Consequently, contemporary research has heavily focused on combination therapy strategies to delay or overcome this resistance. This review synthesizes current literature on gefitinib, detailing its pharmacological activity, molecular mechanisms, and structure-activity relationships. Furthermore, it critically examines the limitations of gefitinib monotherapy and highlights future perspectives, particularly the promising roles of combining gefitinib with chemotherapy, anti-angiogenic agents, selective MET inhibitors, and novel microRNA modulators to optimize patient outcomes.
1. Introduction
Gefitinib (ZD1839, commercially known as Iressa) is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed by AstraZeneca [1]. Selected for clinical development in 1997, it became a pioneering targeted therapy, ultimately receiving approval for the treatment of advanced non-small cell lung cancer (NSCLC) [1]. The discovery that activating mutations in the EGFR gene—most notably in-frame deletions in exon 19 and the L858R point mutation in exon 21—are strong predictors of tumor responsiveness fundamentally shifted the paradigm of NSCLC treatment [1][5][9]. While gefitinib monotherapy yields high objective response rates (ORR) and significantly prolongs progression-free survival (PFS) compared to traditional platinum-based chemotherapy in mutation-positive patients, its long-term success is hindered by acquired resistance, which typically manifests within one year of treatment [4][5]. To address this clinical challenge, extensive research is currently directed toward combination therapy strategies designed to circumvent resistance mechanisms and extend survival [1][2].
2. Pharmacological Activity
Gefitinib exerts its pharmacological effects by potently inhibiting the downstream signaling pathways of the epidermal growth factor receptor [1]. Preclinical and clinical studies demonstrate that gefitinib induces cell cycle arrest—specifically by upregulating p27KIP1 to trigger G1 arrest—and suppresses tumor cell growth and angiogenesis in a dose-dependent and reversible manner [1]. In the clinical setting, landmark trials such as IPASS, WJTOG3405, and NEJ002 established gefitinib's superiority over standard chemotherapy (e.g., carboplatin plus paclitaxel or cisplatin plus docetaxel) as a first-line treatment for patients with EGFR-sensitive mutations, showcasing significantly improved PFS [1][4]. Additionally, gefitinib has shown pharmacological activity in the central nervous system (CNS); it can achieve therapeutic concentrations in the cerebrospinal fluid, providing intracranial disease control for NSCLC patients with brain metastases [9].
3. Molecular Mechanism of Action
At the molecular level, gefitinib functions as a small-molecule inhibitor that competitively blocks the ATP-binding site within the tyrosine kinase domain of EGFR [12]. Under normal physiological conditions, the binding of ligands (such as EGF) to the extracellular domain of EGFR induces receptor dimerization and autophosphorylation. This activates critical intracellular signaling cascades, including the Ras/Raf/MEK/ERK and PI3K/AKT pathways, which promote DNA synthesis, cell proliferation, and survival [9][12]. By reversibly binding to the kinase domain, gefitinib halts this signal transduction, thereby inhibiting tumor invasion, angiogenesis, and the evasion of apoptosis [9].
Recent advancements have also elucidated the role of epitranscriptomics and microRNAs (miRNAs) in modulating gefitinib's mechanism of action. Dysregulation of specific miRNAs—such as miR-155, miR-200c, miR-200a, miR-30a-5p, miR-133a-3p, and miR-483-3p—profoundly affects EGFR crosstalk and cellular sensitivity to gefitinib [12]. For example, miR-200a directly targets EGFR and c-Met mRNAs; its overexpression downregulates these receptors, effectively inhibiting invasion and reversing gefitinib resistance [12]. Similarly, miR-483-3p targets integrin β3 to inhibit the downstream FAK/Erk signaling pathway, reversing epithelial-mesenchymal transition (EMT) and promoting apoptosis in resistant cells [12].
4. Structure-Activity Relationship (SAR)
The structure-activity relationship of gefitinib is fundamentally tied to its interaction with the ATP-binding pocket of the EGFR kinase domain [12]. Activating mutations, such as exon 19 deletions and the L858R point mutation, alter the spatial conformation of the kinase domain. This structural shift significantly increases the receptor's affinity for gefitinib compared to wild-type EGFR, providing the basis for the drug's selective toxicity against mutant cancer cells [5][9]. Conversely, acquired resistance is frequently driven by secondary structural alterations. The most prevalent is the T790M "gatekeeper" mutation in exon 20, which alters the steric configuration of the ATP-binding pocket. This mutation increases the receptor's binding affinity for ATP, allowing ATP to outcompete reversible first-generation inhibitors like gefitinib [5][9]. This structural limitation directly catalyzed the development of irreversible second-generation TKIs (e.g., afatinib) and mutant-selective third-generation TKIs (e.g., osimertinib) [5][9].
5. Current Limitations
The most significant limitation of gefitinib is the inevitable development of acquired drug resistance. While the T790M mutation accounts for over half of these cases, other EGFR-independent mechanisms frequently emerge, including MET amplification, HER2 amplification, and the activation of bypass signaling pathways (e.g., IGF-1R, AXL, and Ras/ERK) [2][5][12].
Toxicity profiles also present substantial clinical limitations, particularly when gefitinib is utilized in combination regimens. While monotherapy is generally associated with manageable adverse events (AEs) like skin rash and diarrhea, severe complications such as hepatotoxicity and fatal interstitial lung disease (ILD) can occur [1][5][7]. Attempts to combine gefitinib with immune checkpoint inhibitors (ICIs) have been particularly problematic; for instance, concurrent use of gefitinib and durvalumab resulted in unexpectedly high incidences of ILD and elevated liver enzymes, leading to the suspension of clinical trials [1]. Furthermore, the phase III IMPRESS trial demonstrated that continuing gefitinib alongside chemotherapy after disease progression provided no overall survival (OS) benefit and actually increased the rate of grade 3 or worse AEs, indicating that this specific combination is detrimental in the resistance setting [2][5]. Nephrotoxicity is also a documented risk when combining targeted agents with certain chemotherapeutics [3].
6. Future Perspectives
To overcome the limitations of monotherapy and acquired resistance, the future of gefitinib lies in rational combination therapy strategies:
Chemotherapy Combinations: Although continuing gefitinib post-resistance is discouraged, its use in combination with chemotherapy in the first-line setting shows significant promise. The NEJ009 study demonstrated that gefitinib combined with carboplatin and pemetrexed improved both PFS and OS in untreated patients compared to gefitinib alone [1][6]. Preclinical models further support this, indicating that combining gefitinib and pemetrexed can prevent the acquisition of TKI resistance in NSCLC cell lines [14].
Targeting Bypass Pathways: For patients developing MET-driven resistance, combining gefitinib with selective MET inhibitors (such as capmatinib or tepotinib) has yielded high response rates in patients with MET amplification or overexpression [1][2][4]. Additionally, combinations with MEK inhibitors (e.g., selumetinib) are being explored to block downstream RAS/RAF/MEK/ERK signaling [2].
Anti-angiogenic Agents: Dual blockade of EGFR and vascular endothelial growth factor (VEGF) pathways is a complementary strategy. Clinical trials have shown that combining gefitinib with angiogenesis inhibitors like apatinib or anlotinib significantly improves median PFS in untreated EGFR-mutated NSCLC patients [1].
Epigenetic and miRNA Modulation: Emerging research highlights the potential of targeting specific miRNAs (e.g., miR-34a, miR-133a-3p) or utilizing deubiquitinase inhibitors (e.g., targeting USP8) to sensitize resistant cells to gefitinib [11][12]. These novel molecular targets, combined with advanced biomarker profiling, hold the potential to refine personalized combination therapies and extend the clinical utility of gefitinib.
